导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.41% | 1389/4773 |
| 近一周 | -2.42% | 2116/5462 |
| 近一月 | -3.81% | 1982/5421 |
| 近一季 | -4.00% | 1519/5209 |
| 近半年 | 2.70% | 944/4920 |
| 近一年 | 7.42% | 1311/4366 |
| 近两年 | 52.18% | 1417/2954 |
| 近三年 | 31.71% | 981/2253 |
| 成立以来 | 60.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.62% 2842/4961 |
12.48% 2170/5312 |
- - |
- - |
| 2025 | 21.95% 2008/4813 |
1.29% 1659/3635 |
2.61% 1464/4076 |
14.07% 2952/4524 |
2.87% 819/4813 |
| 2024 | 14.55% 1037/3463 |
3.67% 525/2808 |
-1.24% 999/3014 |
15.57% 1680/3129 |
-3.19% 2286/3463 |
| 2023 | -11.89% 1432/2656 |
4.09% 1052/2280 |
-3.88% 943/2385 |
-4.03% 1042/2515 |
-8.23% 2269/2655 |
| 2022 | -17.32% 575/2207 |
-10.86% 438/1919 |
7.19% 514/2016 |
-14.18% 1044/2113 |
0.84% 1442/2208 |
| 2021 | 3.80% 601/1822 |
-0.32% 352/1255 |
8.34% 632/1330 |
-4.17% 684/1466 |
0.30% 1141/1822 |
| 2020 | 41.17% 295/1250 |
-7.72% 564/1028 |
14.12% 568/1067 |
17.24% 111/1164 |
14.34% 284/1184 |
| 2019 | - - |
- - |
- - |
0.04% 567/850 |
6.85% 534/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国投瑞银沪深300指数量化增强C VS. 长安沪深300非周期A(740101) |